Retinoids for cancer treatment
Bexarotene
The FDA lists this product in 9 strengths and forms.
Composition
- Active ingredients
- BEXAROTENE 75MG
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- BEXAROTENE 75MG · CapsuleANDA209861-001 · Prescription
- BEXAROTENE 75MG · CapsuleThis page
- BEXAROTENE 75MG · CapsuleANDA208628-001 · Prescription
- BEXAROTENE 75MG · CapsuleANDA209886-001 · Prescription
- BEXAROTENE 75MG · CapsuleANDA203174-001 · Prescription
- BEXAROTENE 1% · GelANDA215398-001 · Prescription
- BEXAROTENE 75MG · CapsuleANDA209931-001 · Prescription
- BEXAROTENE 75MG · CapsuleANDA210105-001 · Prescription
- BEXAROTENE 75MG · CapsuleANDA203663-001 · Prescription
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application ANDA210352.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Bexarotene
- Drug class
- Retinoids for cancer treatment
- Route
- Oral
- Dosage form
- Capsule
- Applicant
- Cipla
- Status
- Discontinued
- FDA approval
- 10 Dec 2024
- Application
- ANDA210352-001
- RxCUI
- 233272